Industry: Cancer treatment

MetasTx is developing a novel drug to treat  prostate cancer. Its formulation, MTX-101, has been shown to suppress the growth of tumor cells and inhibit metastasis into other parts of the body. Importantly, mice-based clinical trials demonstrated no detectable toxicity, unlike many existing cancer treatments.

First developed at UGA, MTX-101 has been shown in tests that it does not deplete testosterone, a critical advancement in this medicine.

The next phase of the company’s research will involve in vivo tests on human, with the aim of producing a safe and effective drug on a commercial scale.

Company website: MetasTx

Back to companies